| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
62,717,000 |
| Market
Cap: |
807.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.12 - $28.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 17.7 |
| Insider 3/6 Months : 18.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viridian Therapeutics is a biotechnology company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications. Co. is developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from TED. Co.'s key program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment for TED. VRDN-002, a distinct IGF-1R antibody is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
476,190 |
476,190 |
911,221 |
| Total Buy Value |
$0 |
$9,999,990 |
$9,999,990 |
$20,261,772 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
4 |
| Total Shares Sold |
0 |
0 |
7,500 |
336,218 |
| Total Sell Value |
$0 |
$0 |
$186,137 |
$10,081,289 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
3 |
20 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fairmount Healthcare Fund Ii L.p. |
|
– • • |
2024-03-28 |
4 |
A |
$0.00 |
$0 |
I/I |
5,859 |
1,845,813 |
|
- |
|
| Fairmount Healthcare Fund Ii L.p. |
|
– • • |
2024-03-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,859) |
0 |
|
- |
|
| Fairmount Healthcare Fund Ii L.p. |
See Remarks |
– • • |
2024-01-22 |
4 |
B |
$21.00 |
$9,999,990 |
I/I |
476,190 |
1,839,954 |
0.01 |
-37% |
|
| Ciulla Thomas |
Chief Medical Officer |
• – – |
2024-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
762 |
|
-41% |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-06 |
4 |
AS |
$25.02 |
$128,253 |
D/D |
(5,126) |
29,971 |
|
-51% |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-06 |
4 |
OE |
$18.51 |
$94,882 |
D/D |
5,126 |
35,097 |
|
- |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-05 |
4 |
AS |
$25.03 |
$12,490 |
D/D |
(499) |
29,971 |
|
-51% |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-05 |
4 |
OE |
$18.51 |
$9,236 |
D/D |
499 |
30,470 |
|
- |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-02 |
4 |
AS |
$24.21 |
$45,394 |
D/D |
(1,875) |
29,971 |
|
-45% |
|
| Meisner Lara |
Chief Legal Officer |
• – – |
2023-06-02 |
4 |
OE |
$14.00 |
$26,250 |
D/D |
1,875 |
31,846 |
|
- |
|
| Myers Scott Dunseth |
Chief Executive Officer |
• • – |
2023-04-12 |
4 |
B |
$25.37 |
$101,479 |
D/D |
4,000 |
259,500 |
0.01 |
-21% |
|
| Myers Scott Dunseth |
Chief Executive Officer |
• • – |
2023-03-13 |
4 |
B |
$29.15 |
$160,324 |
D/D |
5,500 |
255,500 |
0.01 |
-29% |
|
| Meisner Lara |
General Counsel and Secretary |
• – – |
2023-03-09 |
4 |
AS |
$29.07 |
$871,257 |
D/D |
(29,971) |
0 |
|
-26% |
|
| Myers Scott Dunseth |
Chief Executive Officer |
• • – |
2023-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
250,000 |
|
- |
|
| Violin Jonathan |
Chief Executive Officer |
• • – |
2023-02-02 |
4/A |
AS |
$36.80 |
$1,840,000 |
D/D |
(50,000) |
480,905 |
|
- |
|
| Violin Jonathan |
Chief Executive Officer |
• • – |
2023-02-02 |
4/A |
OE |
$0.15 |
$7,500 |
D/D |
50,000 |
530,905 |
|
- |
|
| Violin Jonathan |
Chief Executive Officer |
• • – |
2023-02-02 |
4 |
AS |
$36.80 |
$1,840,000 |
D/D |
(50,000) |
430,905 |
|
-28% |
|
| Meisner Lara |
General Counsel and Secretary |
• – – |
2023-01-23 |
4 |
AS |
$35.66 |
$244,021 |
D/D |
(6,843) |
0 |
|
-31% |
|
| Meisner Lara |
General Counsel and Secretary |
• – – |
2023-01-23 |
4 |
OE |
$14.00 |
$140,690 |
D/D |
6,843 |
6,843 |
|
- |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-17 |
4 |
AS |
$37.21 |
$924,780 |
D/D |
(24,853) |
0 |
|
-37% |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-17 |
4 |
OE |
$23.03 |
$572,365 |
D/D |
24,853 |
24,853 |
|
- |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-13 |
4 |
AS |
$37.01 |
$153,480 |
D/D |
(4,147) |
0 |
|
-34% |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-13 |
4 |
OE |
$23.03 |
$95,505 |
D/D |
4,147 |
4,147 |
|
- |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
AS |
$35.30 |
$1,672,408 |
D/D |
(47,377) |
0 |
|
-35% |
|
| Katz Barrett |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
OE |
$23.03 |
$1,091,092 |
D/D |
47,377 |
47,377 |
|
- |
|
118 Records found
|
|
Page 1 of 5 |
|
|
0.18 (1.42%) 
